FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, Optum and Affiliates

Express Scripts parent company Cigna alleges the Federal Trade Commission ignored more than 3 million pages of documents the pharmacy provided to investigators.

The enforcement action is part of an escalating conflict between the FTC and the three pharmacy benefit managers that together control about 80% of prescriptions filled in the US.

Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and demanded the agency retract a report saying the industry middlemen

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx (a CVS company), Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price

Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade Commission on Tuesday over the regulator's recent drug pricing report, calling the report's conclusion that the prescription middlemen raise drug costs defamatory.

"Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,

The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up insulin prices through anticompe

The Federal Trade Commission has brought an administrative complaint against three of the country's largest pharmacy benefit managers (PBMs), accusing them of engaging in practices that artificially inflated the list price of insulin drugs.